In fact, depletion of macrophages indiscriminately by drugs targeting CSF1 or CSF1R will cause substantial toxicity to normal tissues [4], instead, targeting downstream pro-tumor molecule mediated by CSF1, such as CXCL7, may be a better candidate for future drug development. This evidence concerns the gene CSF1R and neoplasm.